CASI Pharmaceuticals annual depreciation and amortization
2020
2021
2022
2023
2024
2025
CASI Pharmaceuticals Depreciation & Amortization Growth & History (CASIF)
CASI Pharmaceuticals's depreciation and amortization was $1.2M for fiscal 2025.
View full CASI Pharmaceuticals company overviewCASI Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.2M | −$100,000 | −7.69% |
| 2024 | 2024-12-31 | $1.3M | −$1.2M | −48.00% |
| 2023 | 2023-12-31 | $2.5M | $1.3M | +108.33% |
| 2022 | 2022-12-31 | $1.2M | $700,000 | +140.00% |
| 2021 | 2021-12-31 | $500,000 | −$100,000 | −16.67% |
| 2020 | 2020-12-31 | $600,000 | — | — |
CASI Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, CASI Pharmaceuticals's depreciation and amortization increased from $600,000 to $1.2M, a change of $600,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CASI Pharmaceuticals source filings ↗